SLC3A2 and neoplasm: Simultaneously, in lung cancer, SLC3A2 can induce tumour occurrence and metastasis through the MEK/ERK signalling pathway so that it can be used as a prognostic marker, and its serum content can be used to evaluate patient prognosis [86].